Author(s)

Yuejun Du^1,2, Sascha Pahernik³, Matthias Kwol³, Stefan Fuxius⁴, Boris Hadaschik¹, Dogu Teber¹, Stefan Duensing⁵, Annette Kaiser⁶, Markus Hohenfellner¹, Carsten Grüllich^7*

¹Department of Urology, Heidelberg University Hospital, Heidelberg, Germany.
²Department of Urology, Nanfang Hospital of Southern Medical University, Guangzhou, China.
³Department of Urology, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany.
⁴Praxis for Onkologie, Heidelberg, Germany.
⁵Section of Molecular Urooncology, Department of Urology, Heidelberg University Hospital, Heidelberg, Germany.
⁶Clinic for Pathology, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany.
⁷Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.

Objectives: To evaluate treatment and prognosis of collecting duct renal cell carcinoma (CDRCC) in three institutions. Methods: The data of CDRCC patients were collected retrospectively from 3 participating institutions. Results: A total of 24 patients were identified in 3 institutions with an incidence of 0.5% - 0.6%. Among them, the median age was 63.0 years and male gender was predominant (66.7%). At least 45.7% (11/24) of the patients were symptomatic at presentation. Moreover, distant metastasis at initial diagnosis was present in 13 patients (54.2%) and 6 patients (25.0%) developed distant metastasis during the course of disease. Almost all these patients were at high stage (87.5%) and poorly differentiated (79.2%). Besides, nodal involvement and major vein extension were observed in 14 (58.3%) and 10 (41.7%) patients, respectively. All the patients in this cohort underwent surgery with a median cancer specific survival of 11.3 months. Of the 14 patients with chemotherapy, gemcitabine/cisplatin was dominantly given in 6 patients (42.9%). Conclusions: CDRCC is rarely seen. Most of CDRCC patients had advanced stage, high nuclear grade, regional nodal involvement, distant metastasis at presentation and consequent poor prognosis. To date, no standard protocol for the treatment of CDRCC exists. Current standard in systemic therapy of CDRCC is chemotherapy with gemcitabine and cisplatin.

Bellini Duct, Collecting Duct, Prognosis, Renal Cell Cancer, Treatment

Du, Y. , Pahernik, S. , Kwol, M. , Fuxius, S. , Hadaschik, B. , Teber, D. , Duensing, S. , Kaiser, A. , Hohenfellner, M. and Grüllich, C. (2017) Collecting Duct (Bellini Duct) Renal Cell Carcinoma: Oncologic Outcome and Therapeutic Management. Journal of Cancer Therapy, 8, 413-422. doi: 10.4236/jct.2017.85036.